Cargando…

Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer and often is not detected until late stages when cancer cells transcoelomically metastasize to the abdomen and typically become resistant to therapy resulting in very low survival rates. We utilize an orthotopic, syngeneic mouse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenaway, James B., Virtanen, Carl, Osz, Kata, Revay, Tamas, Hardy, Daniel, Shepherd, Trevor, DiMattia, Gabriel, Petrik, Jim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216946/ https://www.ncbi.nlm.nih.gov/pubmed/27329838 http://dx.doi.org/10.18632/oncotarget.10121

Ejemplares similares

The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis
por: Osz, Kata, et al.
Publicado: (2014)

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
por: Cook, David P., et al.
Publicado: (2023)

Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro
por: Correa, Rohann J. M., et al.
Publicado: (2015)

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
por: Knight, Louise A, et al.
Publicado: (2009)

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
por: Göbel, Andy, et al.
Publicado: (2020)

Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma
por: Haagsma, Jacob, et al.
Publicado: (2023)

Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
por: Kobayashi, Yusuke, et al.
Publicado: (2017)

Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models
por: Chen, Apeng, et al.
Publicado: (2023)

Orthotopic and heterotopic ovarian tissue transplantation
por: Demeestere, I., et al.
Publicado: (2009)

Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy
por: Pereira, Madison, et al.
Publicado: (2022)

Development of a syngeneic mouse model of epithelial ovarian cancer
por: Quinn, Bridget A, et al.
Publicado: (2010)

Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours
por: Bochner, Filip, et al.
Publicado: (2020)

Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential
por: Tong, Jessica G., et al.
Publicado: (2017)

Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
por: Abdullah, Marwan Ibrahim, et al.
Publicado: (2017)

Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis
por: Ellis, Leigh, et al.
Publicado: (2014)

Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats
por: Suzuki, Shugo, et al.
Publicado: (2014)

Intact LKB1 activity is required for survival of dormant ovarian cancer spheroids
por: Peart, Teresa, et al.
Publicado: (2015)

Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer
por: Buensuceso, Adrian, et al.
Publicado: (2022)

Tumour antigenicity in ovarian cancer.
por: Levin, L., et al.
Publicado: (1975)

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C
por: Kolendowski, Bart, et al.
Publicado: (2020)

Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis
por: Tong, Jessica G, et al.
Publicado: (2015)

Development of an orthotopic syngeneic murine model of colorectal cancer for use in translational research
por: Evans, Jonathan P, et al.
Publicado: (2019)

A syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis
por: Greenlee, Joshua D, et al.
Publicado: (2022)

The Role of Dysregulated Glucose Metabolism in Epithelial Ovarian Cancer
por: Kellenberger, L. D., et al.
Publicado: (2010)

A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases
por: Wilkinson-Ryan, Ivy, et al.
Publicado: (2018)

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer
por: Russell, Shonagh, et al.
Publicado: (2022)

Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models
por: Nolan, Kyle, et al.
Publicado: (2020)

Akt isoform specific effects in ovarian cancer progression
por: Linnerth-Petrik, Nicolle M., et al.
Publicado: (2016)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

New construction of an animal model for the orthotopic transplantation of an ovarian tumor
por: Zhang, Hui, et al.
Publicado: (2014)

An Advanced Orthotopic Ovarian Cancer Model in Mice for Therapeutic Trials
por: Zhang, Ying, et al.
Publicado: (2016)

Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model
por: Ocak, Meltem, et al.
Publicado: (2014)

Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model
por: Lee, Yooyoung, et al.
Publicado: (2018)

Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model
por: Lin, Kai-Ti, et al.
Publicado: (2017)

Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer
por: Alvero, Ayesha B., et al.
Publicado: (2020)

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
por: Ranoa, Diana Rose E, et al.
Publicado: (2023)

Growth of Syngeneic Tumours in Unimmunized Newborn and Adult Hosts
por: Forni, G., et al.
Publicado: (1973)

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model
por: Watanabe, Fábio T., et al.
Publicado: (2011)

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
por: Anker, Jonathan F., et al.
Publicado: (2018)

Ovarian Tumours and Ovariotomy
Publicado: (1873)

Cannot write session to /tmp/vufind_sessions/sess_jha0ppge7b1b59tfm7aj3rqhqb